CML clonal evolution with resistance to single agent imatinib therapy

R. Swords; J. Quinn; M. Fay; R. O'Donnell; J. Goldman; P. T. Murphy

doi:10.1111/j.1365-2257.2005.00721.x

CML clonal evolution with resistance to single agent imatinib therapy

R. Swords, J. Quinn, M. Fay, R. O'Donnell, J. Goldman, P. T. Murphy

Research output: Contribution to journal › Article › peer-review

9 Scopus citations

Abstract

We describe a 58-year-old male diagnosed with chronic myeloid leukaemia (CML) who failed to have a cytogenetic response to interferon-α and hydroxyurea. On subsequent therapy with imatinib mesylate he failed to have any cytogenetic response but also developed a complex clonal evolution with an additional Philadelphia (Ph) chromosome and trisomy 8 respectively in two Ph-positive subclones. The addition of cytosine arabinoside to imatinib resulted in reversion to single Ph-chromosome positivity with the disappearance of the previous additional clonal abnormalities. The case demonstrates the efficacy of combined treatment with imatinib and cytarabine in the management of CML resistant to single agent imatinib.

Original language	English (US)
Pages (from-to)	347-349
Number of pages	3
Journal	Clinical and Laboratory Haematology
Volume	27
Issue number	5
DOIs	https://doi.org/10.1111/j.1365-2257.2005.00721.x
State	Published - Oct 2005
Externally published	Yes

Keywords

Chronic myeloid leukaemia
Clonal evolution
Imatinib
Philadelphia chromosome
Resistance

ASJC Scopus subject areas

Hematology

Access to Document

10.1111/j.1365-2257.2005.00721.x

Cite this

@article{208cecd1c9a740608fbeafb347dced3a,

title = "CML clonal evolution with resistance to single agent imatinib therapy",

abstract = "We describe a 58-year-old male diagnosed with chronic myeloid leukaemia (CML) who failed to have a cytogenetic response to interferon-α and hydroxyurea. On subsequent therapy with imatinib mesylate he failed to have any cytogenetic response but also developed a complex clonal evolution with an additional Philadelphia (Ph) chromosome and trisomy 8 respectively in two Ph-positive subclones. The addition of cytosine arabinoside to imatinib resulted in reversion to single Ph-chromosome positivity with the disappearance of the previous additional clonal abnormalities. The case demonstrates the efficacy of combined treatment with imatinib and cytarabine in the management of CML resistant to single agent imatinib.",

keywords = "Chronic myeloid leukaemia, Clonal evolution, Imatinib, Philadelphia chromosome, Resistance",

author = "R. Swords and J. Quinn and M. Fay and R. O'Donnell and J. Goldman and Murphy, {P. T.}",

year = "2005",

month = oct,

doi = "10.1111/j.1365-2257.2005.00721.x",

language = "English (US)",

volume = "27",

pages = "347--349",

journal = "Clinical and Laboratory Haematology",

issn = "0141-9854",

publisher = "Wiley-Blackwell",

number = "5",

}

TY - JOUR

T1 - CML clonal evolution with resistance to single agent imatinib therapy

AU - Swords, R.

AU - Quinn, J.

AU - Fay, M.

AU - O'Donnell, R.

AU - Goldman, J.

AU - Murphy, P. T.

PY - 2005/10

Y1 - 2005/10

N2 - We describe a 58-year-old male diagnosed with chronic myeloid leukaemia (CML) who failed to have a cytogenetic response to interferon-α and hydroxyurea. On subsequent therapy with imatinib mesylate he failed to have any cytogenetic response but also developed a complex clonal evolution with an additional Philadelphia (Ph) chromosome and trisomy 8 respectively in two Ph-positive subclones. The addition of cytosine arabinoside to imatinib resulted in reversion to single Ph-chromosome positivity with the disappearance of the previous additional clonal abnormalities. The case demonstrates the efficacy of combined treatment with imatinib and cytarabine in the management of CML resistant to single agent imatinib.

AB - We describe a 58-year-old male diagnosed with chronic myeloid leukaemia (CML) who failed to have a cytogenetic response to interferon-α and hydroxyurea. On subsequent therapy with imatinib mesylate he failed to have any cytogenetic response but also developed a complex clonal evolution with an additional Philadelphia (Ph) chromosome and trisomy 8 respectively in two Ph-positive subclones. The addition of cytosine arabinoside to imatinib resulted in reversion to single Ph-chromosome positivity with the disappearance of the previous additional clonal abnormalities. The case demonstrates the efficacy of combined treatment with imatinib and cytarabine in the management of CML resistant to single agent imatinib.

KW - Chronic myeloid leukaemia

KW - Clonal evolution

KW - Imatinib

KW - Philadelphia chromosome

KW - Resistance

UR - http://www.scopus.com/inward/record.url?scp=26044474546&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=26044474546&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2257.2005.00721.x

DO - 10.1111/j.1365-2257.2005.00721.x

M3 - Article

C2 - 16178920

AN - SCOPUS:26044474546

SN - 0141-9854

VL - 27

SP - 347

EP - 349

JO - Clinical and Laboratory Haematology

JF - Clinical and Laboratory Haematology

IS - 5

ER -

CML clonal evolution with resistance to single agent imatinib therapy

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this